The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma

Journal of B.U.ON.

Volumn 18, Issue 2, 2013, Pages 413-419

  Dirican, Ahmet ^a   Kucukzeybek, Y ^a   Somali, I ^a   Erten, C ^a   Demir, L ^a   Can, A ^a   Bahriye Payzin, K ^a   Vedat Bayoglu, I ^a   Akyol, M ^a   Koseoglu, M ^a   Alacacioglu, A ^a   Oktay Tarhan, M ^a  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

Hematologic parameters; Metastatic renal cell carcinoma; Prognosis; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HISTOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LEUKOCYTE; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84879589892     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. AJCC Cancer Staging Manual (7th Edn). Springer, New York Inc, 2010.
2. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540. (Pubitemid 29368255)
3. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313. (Pubitemid 19014022)
4. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial. Lancet 2001;358:966-970. (Pubitemid 32913522)
5. Kidney. In: AJCC Cancer Staging Manual, Springer, New York, 2009, p 479.
6. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-2771. (Pubitemid 46179466)
7. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10 (18 Pt 2):6302S.
8. Jilma B, Blann A, Pernerstorfer T et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999;159:857-863. (Pubitemid 29137786)
9. Dionigi R, Dominioni L, Benevento A et al. Effects of surgical trauma of laparoscopic vs. open cholecystectomy. Hepatogastroenterology 1994;41:471-476. (Pubitemid 24340646)
10. O'Mahony JB, Palder SB, Wood JJ et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma 1984;24:869-875. (Pubitemid 15183653)
11. Zahorec R. Ratio of neutrophil to lymphocyte counts - Rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14.
12. Smith RA, Bosonnet L, Raraty M et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466-472.
13. Beuselinck B, Oudard S, Rixe O et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22:794-800.
14. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010;184:873-878.
15. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012;187:411-417.
16. Sejima T, Iwamoto H, Morizane S et al The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.Urol Oncol 2011 (Epub ahead of print. http://dx.doi.org/10. 1016/j.urolonc2011.09.008).
17. Keizman D, Ish-Shalom M, Huang P et al.The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma Eur J Cancer 2012;48:202-208.
18. Wang S, Zhang Z, Fang F, Gao X, Sun W, Liu H. The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett 2011;2:735-740.
19. Cedrés S, Torrejon D, Martínez A et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012; 14:864-869.
20. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical Significance of Tumor Pathology for Postoperative Survival of Patients Undergoing Surgery for Stage IV Colorectal Cancer. Anticancer Res 2012;32:3291-3297.
21. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012 :10.1038/bjc.2012.292.
22. Hussein MR, Ahmed RA. Analysis of the mononuclear inflammatory cell infiltrates in the non-tumorigenic, pre-tumorigenic and tumorigenic keratinocytic hyperproliferative lesions of the skin. Cancer Biol Ther 2005;4:819-821.
23. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer related inflammation. Nature 2008;454:436-444.
24. Jarnicki A, Putoczki T, Ernst M. Stat3: Linking inflammation to epithelial cancer - more than a "gut" felling? Cell Div 2010;5:14.
25. Ramsey S. The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell carcinoma. Mol Diagn Ther 2009;13:277-281 (Review).
26. Kudo D, Rayman P, Horton C et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res 2003;63:1676-1683. (Pubitemid 36373661)
27. Rayman P, Uzzo RG, Kolenko V et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Cancer J Sci Am 2000;6 (Suppl 1):S81-S87.
28. Finke JH, Rayman P, George R et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB. Clin Cancer Res 2001; 7 (Suppl 3): 940s-946s. (Pubitemid 33600949)
29. Hase S, Weinitschke K, Fischer K et al. Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep 2011;25:1455-1464.
30. Menges T, Engel J,Welters I et al. Changes in blood lymphocyte populations after multiple trauma: Association with posttraumatic complications. Crit Care Med 1999;27:733-740. (Pubitemid 29218205)
31. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001; 15:61-67. (Pubitemid 32619559)
32. Lip G, Chin B, Blann A. Cancer and prothrombotic state. Lancet 2002; 3: 27-34.
33. Aliustaoglu M, Bilici A, Seker M et al. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 2010;57:640-645.
34. Walsh SR, Cook EJ, Goulder F et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181-184. (Pubitemid 41254421)
35. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y,Fukushima M. The baseline ratio of neutrophils to lymphocytes with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-220. (Pubitemid 351630053)
36. Teramukai S, Kitano T, Kishida Y et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non small cell lung cancer: an analysis of Japan multinational trial organisation LC00-03. Eur J Cancer 2009;45:1950-1958.
37. Tomita M, Shimizu T, Ayabe T, Onitsuka T. Elevated Preoperative Inflammatory Markers Based on Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein Predict Poor Survival in Resected Non-small Cell Lung Cancer. Anticancer Res 2012;32:3535-3538.
38. Keizman D, Ish-Shalom M, Huang P et al.The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.Eur J Cancer 2012; 48: 202-208.